Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus pemetrexed, carboplatin, and bevacizumab after EGFR-TKI failure in T790M-negative EGFR-mutant non-squamous NSCLC
ChiCTR2200062038Phase 2Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Aug 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, pemetrexed, carboplatin and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Xuanwu Hospital. Primary endpoint: Objective response rate. Started Aug 2022; status: recruiting.
02
Drugs
tislelizumabpemetrexedcarboplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200062038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062038.